Format

Send to

Choose Destination
Curr Mol Pharmacol. 2011 Nov;4(3):196-232.

Dry age-related macular degeneration: recent progress of therapeutic approaches.

Author information

1
Research and Development Center, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma-shi, Nara 630-0101, Japan. noriyuki.kuno@gmail.com

Abstract

Age-related macular degeneration (AMD) is a progressive retinal degenerative disease and a common cause of blindness. In AMD, there are two phenotypes; "atrophic (dry)" and "neovascular (wet)". The former is characterized by the geographic atrophy due to death of retinal pigment epithelium, and the latter is developed due to choroidal neovascularization. While wet AMD can be treated by the inhibition of vascular endothelial growth factor or photodynamic therapy, so far there are no available treatments for dry AMD. Fortunately, understanding of pathogenesis in dry AMD has significantly been progressed and many candidates for the treatment of dry AMD have been introduced in clinical trials as well as preclinical stages. In this article, the progress of therapeutic approaches for dry AMD is reviewed.

PMID:
21545354
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center